- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2490
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
CALN1 hypomethylation as a biomarker for high-risk bladder cancer ; volume:22 ; number:1 ; day:9 ; month:11 ; year:2022 ; pages:1-8 ; date:12.2022
BMC urology ; 22, Heft 1 (9.11.2022), 1-8, 12.2022
- Creator
-
Takagi, Kimiaki
Naruse, Azumi
Akita, Kazutoshi
Muramatsu-Maekawa, Yuka
Kawase, Kota
Koie, Takuya
Horie, Masanobu
Kikuchi, Arizumi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12894-022-01136-y
- URN
-
urn:nbn:de:101:1-2023012321513576067452
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Takagi, Kimiaki
- Naruse, Azumi
- Akita, Kazutoshi
- Muramatsu-Maekawa, Yuka
- Kawase, Kota
- Koie, Takuya
- Horie, Masanobu
- Kikuchi, Arizumi
- SpringerLink (Online service)
Other Objects (12)
C14orf166 is a high-risk biomarker for bladder cancer and promotes bladder cancer cell proliferation
DNA hypomethylation and gene expression in bladder cancer
Bladder cancer course, four genetic high-risk variants, and histopathological findings
PAX1 hypomethylation as a prognostic biomarker for radioresistance of cervical cancer
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer
Understanding high-risk business
HSF1 is a novel prognostic biomarker in high-risk prostate cancer that correlates with ferroptosis
C14orf166 is a high-risk biomarker for bladder cancer and promotes bladder cancer cell proliferation
DNA hypomethylation and gene expression in bladder cancer
Bladder cancer course, four genetic high-risk variants, and histopathological findings
PAX1 hypomethylation as a prognostic biomarker for radioresistance of cervical cancer
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer
Understanding high-risk business
HSF1 is a novel prognostic biomarker in high-risk prostate cancer that correlates with ferroptosis
C14orf166 is a high-risk biomarker for bladder cancer and promotes bladder cancer cell proliferation
DNA hypomethylation and gene expression in bladder cancer
Bladder cancer course, four genetic high-risk variants, and histopathological findings
PAX1 hypomethylation as a prognostic biomarker for radioresistance of cervical cancer
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer
Understanding high-risk business